Prestige Consumer Healthcare (PBH) Return on Capital Employed (2011 - 2025)
Prestige Consumer Healthcare (PBH) posted quarterly Return on Capital Employed of 9.68% for Q4 2025, down 58.0% year-over-year from 23.05% in Q4 2024, and down 3.63% quarter-over-quarter from 10.05% in Q3 2025.
Prestige Consumer Healthcare (PBH) Return on Capital Employed (2011 - 2025) Analysis & Trends
Prestige Consumer Healthcare's Return on Capital Employed history runs 15 years deep, the most recent figure standing at 9.68% for Q4 2025.
- In Q4 2025, Return on Capital Employed fell 58.0% year-over-year to 9.68%; the TTM figure through Dec 2025 stood at 9.68% (down 58.0% YoY), while the FY2025 annual figure was 10.35%, down 29.0% from the prior year.
- Return on Capital Employed for Q4 2025 stood at 9.68%, down from 10.05% in the prior quarter.
- The five-year high for Return on Capital Employed was 10.66% in Q1 2024, with the low at 0.76% in Q2 2023.
- The 5-year median for Return on Capital Employed is 9.38% (2022), against an average of 7.63%.
- The sharpest annual moves came in 2023 and 2024: Return on Capital Employed slumped 1010 bps in 2023, then soared 1132 bps in 2024.
- Prestige Consumer Healthcare's Return on Capital Employed stood at 9.16% in 2021, then advanced by 3 bps to 9.45% in 2022, then plunged by 107 bps to 0.65% in 2023, then surged by 1689 bps to 10.26% in 2024, then retreated by 6 bps to 9.68% in 2025.
- Business Quant data shows PBH's Return on Capital Employed at 9.68% in Q4 2025, 10.05% in Q3 2025, and 10.17% in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.94 Bn | 42.97 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 42.95 Bn | 39.30 Bn | 2.15 Bn | 6.60% |
| 3 | Zoetis | 31.58 Bn | 29.90 Bn | 1.05 Bn | 17.16% |
| 4 | Takeda Pharmaceutical | 28.63 Bn | 22.83 Bn | 5.10 Bn | 6.07% |
| 5 | United Therapeutics | 22.16 Bn | 19.49 Bn | 683.80 Mn | 22.04% |
| 6 | Viatris | 18.75 Bn | 17.86 Bn | 1.46 Bn | -0.29% |
| 7 | Neurocrine Biosciences | 15.53 Bn | 15.14 Bn | 935.80 Mn | 18.67% |
| 8 | Elanco Animal Health | 11.76 Bn | 11.23 Bn | 798.00 Mn | 5.52% |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.95 Bn | - | - |
| 10 | Prestige Consumer Healthcare | 2.44 Bn | 2.37 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 9.68% |
| Sep 30, 2025 | 10.05% |
| Jun 30, 2025 | 10.17% |
| Mar 31, 2025 | 10.33% |
| Dec 31, 2024 | 10.26% |
| Sep 30, 2024 | 10.15% |
| Jun 30, 2024 | 10.29% |
| Mar 31, 2024 | 10.66% |
| Dec 31, 2023 | -0.65% |
| Sep 30, 2023 | -0.63% |
| Jun 30, 2023 | -0.76% |
| Mar 31, 2023 | -0.66% |
| Dec 31, 2022 | 9.45% |
| Sep 30, 2022 | 9.39% |
| Jun 30, 2022 | 9.25% |
| Mar 31, 2022 | 9.37% |
| Dec 31, 2021 | 9.16% |
| Sep 30, 2021 | 9.06% |
| Jun 30, 2021 | 9.16% |
| Mar 31, 2021 | 8.94% |